Celtrix Pharmaceuticals, Inc.

Other

Fibrogen, Inc.

Cohesion Technologies, Inc.

David R Olsen

Desmond D Mascarenhas

Yang Zhang

Pamela S Olson

Pedro A Carrillo

Thomas B Neff

Ronald A Hitzeman

Kari I Kivirikko

James W Polarek

Donald G Wallace

Chunlin Yang

Robert Tienhan Chang

Pedro A Cohen

Robert C Chang

George Chisholm

Hugh McMullin

Louis C Sehl

James R Dasch

Patricia R Segarini

Kimyen B Nguyen

Jeff Prior

Kim E Williams

The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.

Recombinant gelatins

Methods are disclosed for simplified recombinant production of fibrillar collagens. DNAs encoding fibrillar collagen monomers lacking the N propeptide, the C propeptide, or both propeptides are introduced into recombinant host cells and expressed. Trimeric collagen is recovered from the recombinant host cells.

Methods for the production of gelatin and full-length triple helical collagen in recombinant cells

New forms of ecarin, a procoagulant protein from venom, are described, as are polynucleotides encoding the new proteins, methods for production of the new proteins, and methods for activation of prothrombin using the new proteins. The new ecarins comprise a serine at position 396 of the protein. The new proteins may be used for activation of prothrombin, and are particularly useful for the production of recombinant thrombin.

Ecarin prothrombin protease and methods

Recombinant gelatin and full-length triple helical collagen

The invention is directed to the use of a fusion partner that does not contain a leader sequence, as a means to increase the solubility and activity of recombinant polypeptides by facilitating the expression of fusion proteins, which are then transported out of the cytoplasm. The invention includes a nucleic acid encoding a fusion polypeptide comprising a mature interleukin-1-like polypeptide or a leader-deleted-translocating polypeptide, and a polypeptide of interest; as well as host cells comprising such nucleic acids, and fusion proteins so encoded. The invention also encompasses methods of using such nucleic acids to produce recombinant fusion polypeptides, mature polypeptides of interest, and purified compositions thereof.

Expression of fusion polypeptides transported out of the cytoplasm

The invention is directed to the use of IL-1-like fusion polypeptides to increase the solubility and activity of recombinant polypeptides. The invention includes a nucleic acid encoding a fusion polypeptide comprising an interleukin-1-like polypeptide and a polypeptide of interest and the method of using such a nucleic acid to produce recombinant fusion polypeptides.

Polypeptide fusions to polypeptides of the beta-trefoil fold structural

A method of treating TGF-.beta. excess is disclosed. The treatment is parenteral, oral or topical administration of TGF-.beta. receptor fragment. Particularly effective is a soluble receptor fragment which resembles the extracellular portion of TGF-.beta. binding protein II.

Uses of TGF-.beta. receptor fragment as a therapeutic agent

Fusion polypeptides and proteins

Growing community of inventors

Menlo Park, CA, United States of America

David R Olsen